BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31902939)

  • 1. Lysophosphatidic Acid Receptor 5 (LPAR5) Plays a Significance Role in Papillary Thyroid Cancer via Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin (mTOR) Pathway.
    Wu CY; Zheng C; Xia EJ; Quan RD; Hu J; Zhang XH; Hao RT
    Med Sci Monit; 2020 Jan; 26():e919820. PubMed ID: 31902939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LPAR5 promotes thyroid carcinoma cell proliferation and migration by activating class IA PI3K catalytic subunit p110β.
    Zhao WJ; Zhu LL; Yang WQ; Xu SJ; Chen J; Ding XF; Liang Y; Chen G
    Cancer Sci; 2021 Apr; 112(4):1624-1632. PubMed ID: 33540491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K/AKT/mTOR signaling pathway.
    Chen L; Zhuo D; Yuan H
    Immunol Lett; 2022 Jun; 246():10-17. PubMed ID: 35447227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
    Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
    Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway.
    Luo X; Wang J; Lu J; Wang X; Miao Y; Li Q; Li X; Wang L
    Biomed Res Int; 2022; 2022():1874550. PubMed ID: 35757470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
    Nowicki TS; Zhao H; Darzynkiewicz Z; Moscatello A; Shin E; Schantz S; Tiwari RK; Geliebter J
    Cell Cycle; 2011 Jan; 10(1):100-7. PubMed ID: 21191179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic pseudogene DUXAP10 knockdown suppresses proliferation and invasion and induces apoptosis of papillary thyroid carcinoma cells by inhibition of Akt/mTOR pathway.
    Li J; Jiang L; Liu Z; Li Y; Xu Y; Liu H
    Clin Exp Pharmacol Physiol; 2020 Aug; 47(8):1473-1483. PubMed ID: 32215944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer.
    Meng L; Zhao P; Hu Z; Ma W; Niu Y; Su J; Zhang Y
    Anticancer Agents Med Chem; 2022; 22(3):596-602. PubMed ID: 33797387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
    Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
    Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-cadherin promotes thyroid tumorigenesis through modulating major signaling pathways.
    Da C; Wu K; Yue C; Bai P; Wang R; Wang G; Zhao M; Lv Y; Hou P
    Oncotarget; 2017 Jan; 8(5):8131-8142. PubMed ID: 28042956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
    Li X; Li Z; Song Y; Liu W; Liu Z
    Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
    Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
    Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
    Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
    Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway.
    Wang SC; Chai DS; Chen CB; Wang ZY; Wang L
    Biomed Pharmacother; 2015 Oct; 75():33-9. PubMed ID: 26463629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway.
    Xu J; Cai J; Jin X; Yang J; Shen Q; Ding X; Liang Y
    Oncol Rep; 2015 Sep; 34(3):1424-30. PubMed ID: 26133772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.
    Fu J; Lv H; Guan H; Ma X; Ji M; He N; Shi B; Hou P
    BMC Cancer; 2013 Oct; 13():462. PubMed ID: 24098937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.